
Scotland approves targetted combination therapy for advanced melanoma
pharmafile | February 11, 2020 | News story | Manufacturing and Production | NHS, SMC, Scotland, UK, advanced melanoma, melanoma
The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic melanoma with a BRAF V600 mutation.
The approval means that encorafenib plus binimetinibi will be used as the first and only targeted therapy available in Scotland for both treatment-naïve and previously treated settings.
This will help improve survival rates. It will more than double median progression-free survival from 7.3 months with BRAF inhibitor monotherapy to 14.9 months. It will also deliver median overall survival from 16.9 months with BRAF inhibitor monotherapy to 33.6 months.
The targeted therapy is already available in the rest of the UK. MASScot, a Scottish melanoma patient group, said the approval is something they have been “pleading for” for a long time. The number of deaths from the disease in Scotland has risen by 20% in the last twenty years.
Melanoma is one of the deadliest forms of skin cancer, and around half of the melanoma patients have a BRAF mutation which has a poorer prognosis and a higher risk of death when the cancer has spread.
Conor Kavanagh
Related Content

“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
People in their forties account for almost three-quarters of those who do not attend NHS …

NIHR chief scientific adviser visits Huddersfield health innovation campus
Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and …






